Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form
Reexamination Certificate
2011-08-23
2011-08-23
Foley, Shanon A (Department: 1648)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
C424S451000, C424S464000
Reexamination Certificate
active
08003118
ABSTRACT:
An oral preparation consisting of a non-systemic antibiotic and a proton pump blocker used for prevention of aspiration pneumonia and sepsis; and a method of prevention of aspiration pneumonia and/or sepsis by orally administering to a subject in need of such treatment a composition containing a therapeutically effective amount of rifaximin.
REFERENCES:
patent: 4341785 (1982-07-01), Marchi et al.
patent: 4557866 (1985-12-01), Cannata et al.
patent: 5314904 (1994-05-01), Egidio et al.
patent: 5352679 (1994-10-01), Ferrieri et al.
patent: 5886002 (1999-03-01), Ferrari et al.
patent: 6140355 (2000-10-01), Egidio et al.
Doson et al. The Annals of Pharmacotherapy. 2007; 41 (4): 647-52, abstract only.
Hunter et al. European Journal of Anaesthesiology. 2007; 24: 971-977.
Definition of “sepsis”, provided by Stedman's medical dictionary, 27th edition (online), 2005 copyright.
Drugdex Drug Evaluations for Rifaximin; MICROMEDEX® Healthcare Series (Sep. 2004).
“Spectroscopic Investigation of the Conformational Properties and Self-Association Behavior of Natural Compounds in Solution” published in Spectroscopy Letters, vol. 35, Issue 4 Aug. 14, 2002.
News Article titled “Salix Pharmaceuticals' New Drug Application for LUMENAX Rifaximin for the Treatment of Travelers Diarrhea Accepted for Filing by FDA”, Business Editors and Health/Medical Writers Feb. 25, 2002.
www.drugs.com webpage for Xifaxan® (Salix Pharmaceuticals' trade name for Rifaximin®) and consumer questions; revision date Jun. 7, 2004.
Listing from www.rxlist.com stating chemical name and empirical formula for Xifaxan® printed Feb. 7, 2005.
Listing from FDA website (www.fda.gov) regarding XIFAXAN® stating general information about drug; posted Aug. 12, 2004.
Information regarding Xifaxan from the Salix Pharmaceutical's website and results of a study which suggested potential use of Xifaxan in the prevention of Shigellosis Nov. 9, 2004.
XIFAXAN™ datasheet from Salix Pharmaceuticals Inc, NC, Jun. 2004.
www.buy-online-prescription.com listing for the trade name Rifaximine printed Feb. 9, 2005.
www.buy-online-prescription.com listing for trade name Normix printed Feb. 9, 2005.
www.buy-online-prescription.com listing for trade name Flonorm printed Feb. 9, 2005.
www.buy-online-prescription.com listing for trade name Redactiv printed Feb. 9, 2005.
Sheet from www.healthatoz.com with general info about Traveler's Diarrhea and use of Normix to treat it; printed Feb. 9, 2005.
Article titled “Revenge on Montezuma's Revenge,” Health Day News printed Feb. 8, 2005.
Brief description of a preliminary study done with Rifaximin from University of Bologna, J Int Med Res. Jul.-Aug. 1988 16(4).
Article titled “EnteroaggregativeEscherichia coliDiarrhea in Travelers: Response to Rifaximin Therapy,” Clinical Gastroenterology and Hepatology vol. 2, No. 2 Feb. 2004.
Article titled “Therapy of Travelers' Diarrhea With Rifaximin on Various Continents,” The American Journal of Gastroenterology vol. 98 No. 5 May 2003.
Chapter 38 from Merck Manual regarding Pneumonia p. 681-691, Mar. 1999.
Definition of Pneumonia from www.wikipedia.org printed Feb. 10, 2005.
Foley Shanon A
Onofrio Law
Onofrio, Esq. Dara L.
LandOfFree
Use of rifaximin for the prevention of aspiration pneumonia... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of rifaximin for the prevention of aspiration pneumonia..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of rifaximin for the prevention of aspiration pneumonia... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2741477